+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Growth Opportunities in Gene Therapy, Automated Bioanalytics, and Biomarker Platforms

  • ID: 5150058
  • Report
  • July 2020
  • Region: Global
  • 66 Pages
  • Frost & Sullivan

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abcordia Ltd.
  • Beckley Psytech
  • Caspr Biotech
  • Elisa Technologies
  • Freeline Therapeutics
  • MGB Biopharma Ltd.
  • MORE

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) encompasses recent advances in gene therapy, automated bioanalytics, drug discovery technologies, biomarker platforms, and targeted delivery. The research also provides technological insights across inflammation, infectious diseases, and microbiomics.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abcordia Ltd.
  • Beckley Psytech
  • Caspr Biotech
  • Elisa Technologies
  • Freeline Therapeutics
  • MGB Biopharma Ltd.
  • MORE

Growth Opportunities in Gene Therapy, Automated Bioanalytics, and Biomarker Platforms

Innovations in Life Sciences, Health & Wellness

  • Freeline Therapeutics, UK
  • Growth Opportunities
  • Nodthera, UK
  • Growth Opportunities
  • CEM Corporation, US
  • Growth Opportunities
  • Elementar Analysensysteme Gmbh, Germany
  • Growth Opportunities
  • Apitope Technology Ltd., UK
  • Growth Opportunities
  • MGB Biopharma Ltd., UK
  • Growth Opportunities
  • Reviral Ltd., UK
  • Growth Opportunities
  • Mina Therapeutics Limited, UK
  • Growth Opportunities
  • Abcordia Ltd., UK
  • Growth Opportunities
  • Genome Medical, US
  • Growth Opportunities
  • Biogen, US
  • Growth Opportunities
  • Hong Kong University of Science and Technology, Hong Kong
  • Growth Opportunities
  • Amryt, UK
  • Growth Opportunities
  • Uniqure NV, Netherlands
  • Growth Opportunities
  • Caspr Biotech, Argentina
  • Growth Opportunities
  • Travecta Therapeutics, Singapore
  • Growth Opportunities
  • Wistar Institute, US
  • Growth Opportunities
  • E-Therapeutics, UK
  • Growth Opportunities
  • Enterome, France
  • Growth Opportunities
  • Elisa Technologies, US
  • Growth Opportunities
  • Cutiss, Switzerland
  • Growth Opportunities
  • Beckley Psytech, UK
  • Growth Opportunities
  • Pharnext, France
  • Growth Opportunities
  • Children’s Hospital of Philadelphia, US
  • Growth Opportunities
  • Incelldx, US
  • Growth Opportunities
  • Biochrom, UK
  • Growth Opportunities

Key Contacts

  • Legal Disclaimer
Note: Product cover images may vary from those shown
  • Abcordia Ltd.
  • Amryt
  • Apitope Technology Ltd.
  • Beckley Psytech
  • Biochrom
  • Biogen
  • Caspr Biotech
  • CEM Corporation
  • Children’s Hospital of Philadelphia
  • Cutiss, Switzerland
  • E-Therapeutics
  • Elementar Analysensysteme Gmbh
  • Elisa Technologies
  • Enterome
  • Freeline Therapeutics
  • Genome Medical
  • Hong Kong University of Science and Technology
  • Incelldx
  • MGB Biopharma Ltd.
  • Mina Therapeutics Limited
  • Nodthera
  • Pharnext
  • Reviral Ltd.
  • Travecta Therapeutics
  • Uniqure NV
  • Wistar Institute
Note: Product cover images may vary from those shown
Adroll
adroll